Toronto – April 23, 2012 – Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY) has invested $1.3 million in a “condensing economizer”. The cutting-edge equipment, which is the size of a small building, converts waste heat into energy. The investment was part of Sanofi Pasteur’s ongoing commitment to reducing its environmental impact and promises to reduce the site’s carbon dioxide emissions by more than 2,300 tonnes per year.

Mark Lievonen, President of Sanofi Pasteur Limited, says "these results make the installation well worth it. We’re proud of Sanofi Pasteur’s commitment to preventing pollution, protecting the environment, and conserving energy and natural resources in order to achieve sustainable development for the benefit of current and future generations.”

Enbridge Gas Distribution, Canada’s largest natural gas distribution utility, conducted a complete assessment of Sanofi Pasteur’s boiler plant performance in March 2011 and presented energy savings recommendations to Sanofi Pasteur’s Energy Task Force in Toronto.

“Enbridge was proud to help Sanofi Pasteur identify opportunities for significant energy efficiency measures in its operations,” said Andrew Mandyam who manages energy efficiency programs at Enbridge Gas Distribution. “Through its leadership, Sanofi Pasteur is proving that energy efficiency measures can make not only environmental sense, but business sense by saving money as well.”

Through Enbridge’s energy efficiency Industrial Demand Side Management Program, Sanofi Pasteur received a financial incentive grant of $200,000 toward the implementation of this efficiency measure.

“As a manufacturing site, we have a responsibility to look at every opportunity we have to conserve energy. By working with Enbridge Gas Distribution and installing the condensing economizer, we were able to make a significant dent in our energy consumption,” said Melanee Short, Sanofi Pasteur’s Deputy Director, Environment and Sustainability, responsible for environmental initiatives.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: or

Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.


Canadian Media Relations
Nancy Simpson
T. 416-667-2955